Impact News +++ INOVIO Pharmaceuticals proposes securities offering (SeekingAlpha) +++ INOVIO Aktie -12,75%

TUHURA Aktie

>TUHURA Aktienkurs

1.39 EUR (TradegateBSX)

Ask: 1.41 EUR / 3489 Stück

Bid: 1.37 EUR / 3632 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TUHURA Aktie über LYNX handeln

Intraday

1 Jahr

>TUHURA Performance

1 Woche: -20,7%

1 Monat: -5,7%

3 Monate: +108,2%

6 Monate: -34,8%

1 Jahr: 0%

laufendes Jahr: +108,2%

>TUHURA Aktie

Name:

TUHURA BIOSCIENCES INC.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8989201038 / A3EWMJ

Symbol/ Ticker:

PL3 (Frankfurt) / HURA (NASDAQ)

Kürzel:

FRA:PL3, ETR:PL3, PL3:GR, NASDAQ:HURA

Index:

Webseite:

https://tuhurabio.com/

Profil:

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company focused on developing innovative therapeutics that aim to overcome both primary and acquired resistance to cancer immunotherapies. The company leverages its proprietar..
>Volltext..

Marktkapitalisierung:

90.83 Mio. EUR

Unternehmenswert:

89.27 Mio. EUR

Umsatz:

EBITDA:

-21.92 Mio. EUR

Nettogewinn:

-25.32 Mio. EUR

Gewinn je Aktie:

-0.56 EUR

Schulden:

0.5 Mio. EUR

Liquide Mittel:

2.33 Mio. EUR

Operativer Cashflow:

-21.33 Mio. EUR

Bargeldquote:

0.31

Umsatzwachstum:

Gewinnwachstum:

-132.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TUHURA

Letzte Datenerhebung:

02.04.26

>TUHURA Kennzahlen

Aktien/ Unternehmen:

Aktien: 60.72 Mio. St.

Frei handelbar: 75.32%

Leerverk. Aktien: 12.75%

Rückkaufquote: -15.2%

Mitarbeiter: 19

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 372.08%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 6.09

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -110.91%

Eigenkaprendite: -418.06%

>TUHURA Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Antikörper- Behandlung

>TUHURA Chart & Kurs - NASDAQ

>TUHURA News

01.04.26 - 14:09	TuHURA Biosciences reports FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.26 - 13:48	TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter......

23.03.26 - 12:48	Craig Tendler, M.D., JNJ′s Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience′s VISTA Program in AML and other Blood Related Cancers (PR Newswire)
	Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four......

27.02.26 - 16:54	TuHURA Biosciences: Aktie legt nach Erfüllung der NASDAQ-Anforderungen zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 13:33	TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
	TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written......

24.02.26 - 23:24	TuHURA Biosciences Announces Participation in Upcoming Investor Conferences (PR Newswire)
	TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief......

17.02.26 - 13:48	TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers (PR Newswire)
	TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AML TAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to......

12.02.26 - 13:48	TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire)
	TAMPA, Fla., Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief......

02.02.26 - 13:48	TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma (PR Newswire)
	TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA)......

15.12.25 - 13:54	TuHURA Biosciences Announces its Release of Kintara′s Contingent Value Right (CVR) as Kintara′s REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone (PR Newswire)
	Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders TAMPA, Fla., Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to......

11.12.25 - 13:33	TuHURA Biosciences Provides Corporate Update Following Recent Financing (PR Newswire)
	Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA)......

09.12.25 - 15:51	TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering (PR Newswire)
	TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for......

08.12.25 - 13:54	TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition (PR Newswire)
	Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced......

14.11.25 - 13:33	TuHURA Biosciences GAAP EPS of -$0.14 beats by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.25 - 13:03	TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug......

03.11.25 - 15:48	TuHURA Biosciences: Aktie legt nach Annahme von Krebsforschung für wichtige Konferenz zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.11.25 - 15:03	TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition (PR Newswire)
	Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer......

20.08.25 - 14:06	TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
	TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright......

15.08.25 - 04:36	TuHURA R&D Jumps 75% in Q2 (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:18	TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor in 2H 2025 Initiated a Phase 3......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Don′t marry, be happy. - Hera Lind

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram